摘要
目的:观察人尿激肽原酶(尤瑞克林)在急性脑梗死治疗中的有效性和安全性。方法:对30例急性脑梗死患者给予单用尤瑞克林治疗2周,治疗前后以NIHSS、mRS量表评价疗效。结果:治疗后30例患者NIHSS评分低于治疗前,差异有统计学意义(P<0.05);mRS评分低于治疗前,有显著性差异(P<0.01)。基本痊愈4例,显著进步16例,进步5例,无变化4例,恶化1例,总显效(基本痊愈+显著进步)20例。出现恶心呕吐者2例,转氨酶增高者1例,所有治疗未见血压明显下降(下降>30%)。血尿常规、血糖、血脂、肾功能未见明显变化。结论:应用尤瑞克林治疗急性脑梗死安全且临床疗效肯定。
Objective： To investigate the efficacy and safety of Human Urinary Kallidinogenase Injection in patients with acute cerebral infarction（ACI）.Methods： Thirty ACI patients were divided into the control group and Human Urinary Kallidinogenase group in which Human Urinary Kallidinogenase were used for 14 days.The patients were evaluated by the National Institutes of Health Stroke Scale（NIHSS） and the Modified Rankin Scale（mRS） before and after the therapy.Results： Two weeks after the treatment,the patients were improved significantly.Conclusion： Human Urinary Kallidinogenase Injection is effective in treating ACI.
出处
《神经损伤与功能重建》
2008年第5期321-322,共2页
Neural Injury and Functional Reconstruction
关键词
尤瑞克林
急性脑梗死
有效性
安全性
Kallikrein
acute cerebral infarction
efficacy
safety
